secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sana Biotechnology, Inc. (SANA)
CIK:        0001770121
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001193125-26-053294
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sana Biotechnology appoints Brian Piper as EVP, CFO; base salary $515K, option grant of 900K shares
--------------------------------------------------------------------------------

- Brian Piper appointed EVP, CFO and Treasurer effective February 17, 2026; replaces Steven Harr as acting principal financial officer.
- Annual base salary of $515,000 with target bonus of 40% of base salary.
- Granted option to purchase 900,000 shares (25% vest year 1, then monthly) and 200,000 RSUs (4-yr annual vest).
- Piper previously CFO at Scorpion Therapeutics, Antares Therapeutics, and Prelude Therapeutics; over 25 years biopharma finance experience.
- Company expects initial clinical data for SC451 (type 1 diabetes) and SG293 (B-cell disease) in next 12-18 months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526053294/0001193125-26-053294-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770121/000119312526053294/sana-20260217.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-053294

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer